Use of sodium oxybate and low-sodium oxybate led to meaningful improvements in patients with hypersomnia and narcolepsy regardless of comorbidities.
Both hypersomnia and narcolepsy can be treated using sodium oxybate or low-sodium oxybate, according to abstracts presented at the SLEEP 2024 Annual Meeting held in Houston, Texas from June 1 to June 5, 2024. Improvements in narcolepsy were not affected by the number of comorbidities possessed by the patient.
Low-sodium oxybate (LXB) is a treatment for cataplexy or daytime sleepiness that has been approved by the FDA for usage in patients aged 7 years and older who have been diagnosed with narcolepsy or idiopathic hypersomnia (IH). LXB contains approximately 92% less sodium than sodium oxybate (SXB), which can be used in IH. These 2 studies tested the efficacy of SXB in patients with IH and the efficacy and safety of LXB in patients with narcolepsy both with and without psychiatric or neurologic comorbidities.
Man sleeping | Image credit: Laflor/peopleimages.com - stock.adobe.com
In the first study,1 the researchers used the Epworth Sleepiness scale (ESS), the Idiopathic Hypersomnia Severity Scale (IHSS), and the Maintenance of Wakefulness Test (MWT) assessment to survey the participants for improvements in sleep. All participants were aged 18 to 60 years, were diagnosed with IH, and had a ESS of 14 or higher. The participants were randomly assigned 1:1 to either receive SXB or placebo. Treatment was given for 2 weeks at a stable dose of either 6g or 9g before being tapered off for a week. Mean change in ESS from baseline to week 8 acted as the primary endpoint, with changes in sleep latency on the MWT and IHSS acting as secondary endpoints.
There were 45 patients who were randomly assigned to the 2 groups. The majority of participants were women (n = 36) with a mean (SD) age of 29.0 (7.5) years and a mean ESS of 16.5 (2.7). Meanwhile, 22 were assigned to the SXB group. A total of 40 participants completed the double-blind period, of which 19 were receiving SXB.
The between-group differences for SXB vs placebo had a mean change in ESS from baseline to endpoint of –6.54 (95% CI, –9.35 to –3.73). Between group differences for average sleep latency from baseline to endpoint were 13.87 (95% CI, 8.35-19.39) for the MWT and –10.87 (95% CI, –15.71 to –6.03) in the IHSS. A total of 77% of patients reported adverse events due to treatment in the SXB group vs 30% in the placebo group. These adverse events included nausea, headache, and dizziness.
The researchers concluded that a clinically meaningful improvement was found in patients with IH who were using SXB. Excessive sleepiness, as measured by ESS, and wakefulness, as measured by the MWT, both improved when using SXB and the efficacy was similar to that of previous studies.
The second study2 focused on a phase 3 trial testing the safety and efficacy of LXB for patients with narcolepsy both with and without psychiatric or neurologic comorbidities. All participants were aged 18 to 70 years and were diagnosed with narcolepsy with cataplexy.
Participants had an optimized/titrated dose of LXB for up to 12 weeks before a stable dose period of 2 weeks. Participants either stayed on LXB or were switched to a placebo in the 2-week double-blind randomized-withdrawal period. Participants both with and without comorbidities were evaluated using the ESS, average weekly number of cataplexy attacks, thePatient Health Questionnaire-9 scores, the Patient Global Impression of Change, and treatment-emergent adverse effects (TEAE).
There were 201 participants in this study, of which 84 reported a comorbidity at baseline, most commonly depression, migraines, anxiety, and regular headaches. Participants who were switched to the placebo had worse ESS scores compared with participants who continued with LXB both with comorbidities (–3.7; 95% CI, –5.6 to –1.9) and without (–2.0; 95% CI, –3.5 to –0.6). Participants in the placebo group also had more weekly cataplexy attacks compared with those in the LXB group both with (–4.0; 95% CI, –7.0 to –1.1) and without (–3.5; 95% CI, –9.1 to –1.1) comorbidities. PGIc was also worse in patients on the placebo treatment and depression remained stable.
TEAEs and serious TEAEs were found in 82.1% and 1.2% of participants with comorbidities and 71.8% and 2.6% of participants without comorbidities. The researchers concluded that LXB was both safe and effective in patients who had psychiatric or neurologic comorbidities, as the safety and efficacy was similar to that of the patients who had no comorbidities.
“The major takeaway is that in patients with narcolepsy who have psychiatric and neurological comorbidities. [LXB] works just as well in those individuals than those that don't have those issues,” said Nathaniel Watson, MD, MSc, a coauthor of the study. “It can help assure providers and patients that this medication can be safe and effective in those with psychiatric and neurological disorders.”
Overall, SXB and LXB are both safe and effective treatments for patients with either narcolepsy or IH.
References
New Insights Into Meth-Associated PAH Care Gaps: Insights From Anjali Vaidya, MD
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Depth of Responses, PFS in Transplant-Ineligible Patients Match Overall Findings in CEPHEUS
June 2nd 2025Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; there is debate whether all newly diagnosed patients should have this regimen.
Read More
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More